We reported a series of immune checkpoint interaction pairs, including CTLA4-CD86, TIGIT-PVR, LGALS9-HAVCR2, and TNFSF4-TNFRSF4, which could offer further insights for the discovery and development of new therapeutic agents for ESCC. This evidence concerns the gene CD86 and esophageal squamous cell carcinoma.